Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Esperion Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Esperion Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
Details : Neopharm Israel gains exclusive rights to commercialize Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Israel for cardiovascular disease.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Esperion Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Amarin
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Amarin has appointed Neopharm as its sole and exclusive distributor of Vazkepa (icosapent ethyl) approved to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglyce...
Product Name : Vazkepa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 08, 2023
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Amarin
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Mirum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome (ALGS).
Product Name : Livmarli
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Maralixibat Chloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Mirum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Recipient : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the revenue sharing agreement, Neopharm gains exclusive rights to commercialize QRX003 in Israel. Quoin will be the exclusive supplier of QRX003 to Neopharm.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 17, 2022
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Recipient : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Amylyx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm
Details : Albrioza (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) in Canada and with marketing applications pending in the United States and European Union.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2022
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Amylyx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
UroGen Pharma Announces License and Supply Agreement with Neopharm
Details : Neopharm will lead the regulatory process in Israel, which is supported by the results from the Phase 3 OLYMPUS trial that showed Jelmyto achieved clinically significant disease eradication in adults with LG-UTUC.
Product Name : Jelmyto
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : Mitomycin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : UroGen Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement